| Flk-1 as a target for tumor growth inhibition LM Strawn, G McMahon, H App, R Schreck, WR Kuchler, MP Longhi, ... Cancer Research 56 (15), 3540-3545, 1996 | 457 | 1996 |
| High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter C Özvegy-Laczka, T Hegedűs, G Várady, O Ujhelly, JD Schuetz, A Varadi, ... Molecular pharmacology 65 (6), 1485-1495, 2004 | 414 | 2004 |
| AXL is a potential target for therapeutic intervention in breast cancer progression YX Zhang, PG Knyazev, YV Cheburkin, K Sharma, YP Knyazev, L Orfi, ... Cancer research 68 (6), 1905-1915, 2008 | 262 | 2008 |
| Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties C Hegedűs, C Özvegy‐Laczka, A Apati, M Magocsi, K Nemet, L Őrfi, ... British journal of pharmacology 158 (4), 1153-1164, 2009 | 258 | 2009 |
| Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1 T Hegedűs, L Őrfi, A Seprődi, A Váradi, B Sarkadi, G Kéri Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002 | 254 | 2002 |
| Treatment of platelet derived growth factor related disorders such as cancers KP Hirth, E Mann, LK Shawyer, A Ullrich, I Szekely, T Bajor, J Haimichael, ... US Patent 6,331,555, 2001 | 205* | 2001 |
| Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors S Blencke, B Zech, O Engkvist, Z Greff, L Őrfi, Z Horváth, G Kéri, A Ullrich, ... Chemistry & biology 11 (5), 691-701, 2004 | 177 | 2004 |
| Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes A Herrero, A Pinto, P Colón-Bolea, B Casar, M Jones, L Agudo-Ibáñez, ... Cancer cell 28 (2), 170-182, 2015 | 156 | 2015 |
| Acid− base profiling of imatinib (gleevec) and its fragments Z Szakács, S Béni, Z Varga, L Örfi, G Kéri, B Noszál Journal of medicinal chemistry 48 (1), 249-255, 2005 | 145 | 2005 |
| Reliability of logP predictions based on calculated molecular descriptors: a critical review D Eros, I Kovesdi, L Orfi, K Takacs-Novak, G Acsády, G Kéri Current medicinal chemistry 9 (20), 1819-1829, 2002 | 138 | 2002 |
| NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling SA Barman, F Chen, Y Su, C Dimitropoulou, Y Wang, JD Catravas, W Han, ... Arteriosclerosis, thrombosis, and vascular biology 34 (8), 1704-1715, 2014 | 134 | 2014 |
| Leads for antitubercular compounds from kinase inhibitor library screens S Magnet, RC Hartkoorn, R Székely, J Pató, JA Triccas, P Schneider, ... Tuberculosis 90 (6), 354-360, 2010 | 125 | 2010 |
| Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling K Godl, OJ Gruss, J Eickhoff, J Wissing, S Blencke, M Weber, H Degen, ... Cancer Research 65 (15), 6919-6926, 2005 | 122 | 2005 |
| Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion J Rybniker, JM Chen, C Sala, RC Hartkoorn, A Vocat, A Benjak, ... Cell Host & Microbe 16 (4), 538-548, 2014 | 106 | 2014 |
| A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling R Székely, F Wáczek, I Szabadkai, G Németh, B Hegymegi-Barakonyi, ... Immunology letters 116 (2), 225-231, 2008 | 106 | 2008 |
| Application of neural networks in structure–activity relationships I Kövesdi, MF Dominguez‐Rodriguez, L Ôrfi, G Náray‐Szabó, A Varró, ... Medicinal research reviews 19 (3), 249-269, 1999 | 102 | 1999 |
| Treatment of platelet derived growth factor related disorders such as cancers KP Hirth, DP Schwartz, E Mann, LK Shawver, G Keri, I Szekely, T Bajor, ... US Patent 5,700,823, 1997 | 90 | 1997 |
| Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors G Németh, Z Greff, A Sipos, Z Varga, R Székely, M Sebestyén, Z Jászay, ... Journal of medicinal chemistry 57 (10), 3939-3965, 2014 | 85 | 2014 |
| Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer … C Hegedüs, K Truta-Feles, G Antalffy, G Várady, K Nemet, ... Biochemical pharmacology 84 (3), 260-267, 2012 | 84 | 2012 |
| Quantitative analysis of peptides with NMR spectroscopy CK Larive, D Jayawickrama, L Orfi Applied Spectroscopy 51 (10), 1531-1536, 1997 | 84 | 1997 |
Dániel ErősVerified email at vichem.hu
